Inmune Bio Inc Stock: Recent 2025 Results Highlight Late-Stage Pipeline Progress Amid Cash Runway to Q1 2027

INmune Bio Inc (NASDAQ: INMB, ISIN: US45764T1060) released 2025 financial results on March 30, 2026, detailing advances in CORDStrom and XPro programs with key regulatory filings ahead, while cash provides runway through Q1 2027 on the NASDAQ exchange in USD.

Inmune Bio Inc, trading as INMB on NASDAQ in USD under ISIN US45764T1060, announced its full-year 2025 financial results and business update on March 30, 2026. The late-stage biotechnology company, focused on inflammation and immunology, outlined progress toward key regulatory submissions for its lead assets CORDStrom and XPro.

As of: 31.03.2026

By Dr. Elena Hargrove, Senior Biotech Analyst at NorthStar Market Insights: INmune Bio Inc advances novel immunology therapies targeting unmet needs in neuroinflammation and beyond.

Recent Financial Results and Business Update

The company reported a net loss of $45.9 million for the year ended December 31, 2025, compared to $42.1 million in 2024. This included a $16.5 million impairment charge on acquired in-process research and development.

Cash and cash equivalents stood at $24.8 million as of year-end, bolstered by a $3.6 million Australian R&D rebate received in January 2026, providing a runway through Q1 2027.

During 2025, Inmune Bio raised $27.5 million in net proceeds from selling 4.3 million shares, including $17.4 million from a registered direct offering and $10.1 million from at-the-market offerings.

Pipeline Catalysts: CORDStrom Toward Regulatory Filings

CORDStrom, a cell therapy for acute respiratory distress syndrome, has completed three pilot commercial manufacturing runs. The company plans a Marketing Authorization Application submission to the UK MHRA in mid-summer 2026, followed by EMA and a U.S. Biologics License Application in Q4 2026.

This timeline aligns closely with the cash runway, positioning potential approvals as critical milestones ahead of Q1 2027.

CEO David Moss highlighted the transition to a late-stage, registration-directed organization, emphasizing CORDStrom's role in harnessing the innate immune system for inflammatory diseases.

XPro Program in Alzheimer's: FDA Alignment Achieved

XPro, targeting neuroinflammation in early Alzheimer’s, has secured FDA alignment for an adaptive Phase 2b/3 registrational pathway following an End-of-Phase 2 meeting in February 2026.

The biomarker-enriched design targets patients with neuroinflammation, supported by MINDFuL trial data presented at AD/PD 2026. No cases of amyloid-related imaging abnormalities have been reported across XPro studies.

This precision approach aims to de-risk development compared to traditional all-comer trials.

Business Model and Immunology Focus

INmune Bio develops therapies modulating the innate immune system to treat cancer, Alzheimer’s, and inflammatory diseases. The platform targets Disease Altering Macrophage Therapy, reprogramming dysfunctional myeloid cells.

CORDStrom uses umbilical cord-derived stromal cells to reduce lung inflammation in ARDS, while XPro inhibits soluble TNF without impacting transmembrane TNF.

The company prioritizes capital allocation to these late-stage assets, maintaining a lean operation in Boca Raton, Florida.

Relevance for North American Investors

For U.S. investors, INMB offers exposure to high-unmet-need areas like ARDS and early Alzheimer’s via NASDAQ-listed shares in USD. Regulatory catalysts in UK, EU, and FDA pathways provide multiple shots at commercialization.

The sub-$2 share price reflects biotech volatility but positions the stock for potential re-rating on filing successes or data readouts.

North American focus intensifies with the Q4 2026 FDA BLA for CORDStrom and ongoing XPro advancement.

Risks and Key Factors to Watch

Cash runway extends only to Q1 2027, risking dilutive financing if milestones slip. Execution on tight timelines for MAA/BLA submissions remains critical.

Biotech risks include regulatory hurdles, trial enrollment, and manufacturing scale-up for CORDStrom. The 2025 impairment underscores R&D uncertainties.

Investors should monitor mid-summer 2026 MHRA filing, Q4 BLA submission, XPro Phase 2b/3 initiation, quarterly cash updates, and any partnership announcements.

Disclaimer: Not investment advice. Stocks are volatile financial instruments.